Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ COVID-19 case 63% Improvement Relative Risk Ferri et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 1,641 patients in Italy Fewer cases with HCQ (p=0.015) Ferri at al., Clinical Rheumatology, doi:0.1007/s10067-020-05334-7 Favors HCQ Favors control
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
Ferri at al., Clinical Rheumatology, doi:0.1007/s10067-020-05334-7
Ferri, COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series, at al., Clinical Rheumatology, doi:0.1007/s10067-020-05334-7
Aug 2020   Source   PDF  
  All Studies   Meta
Analysis of 1641 systemic autoimmune disease patients showing csDMARD (HCQ etc.) RR 0.37, p=0.015.
csDMARDs include HCQ, CQ, and several other drugs, so the effect of HCQ/CQ alone could be higher.
This study also confirms that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, OR 4.42, p<0.001 (this is the observed real-world risk which takes into account factors such as these patients potentially being more careful to avoid exposure).
(results are for "definite + highly suspected" cases and the main result is presented in the paper as the OR for not taking csDMARDs, we have converted this to RR for taking csDMARDs).
risk of COVID-19 case, 63.0% lower, RR 0.37, p = 0.01, treatment 9 of 994 (0.9%), control 16 of 647 (2.5%), NNT 64.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ferri et al., 27 Aug 2020, retrospective, Italy, peer-reviewed, survey, 29 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Clinical Rheumatology (2020) 39:3195–3204 ORIGINAL ARTICLE COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series Clodoveo Ferri 1,2 & Dilia Giuggioli 1 & Vincenzo Raimondo 2 & Massimo L’Andolina 3 & Antonio Tavoni 4 & Riccardo Cecchetti 5 & Serena Guiducci 6 & Francesco Ursini 7 & Maurizio Caminiti 8 & Giuseppe Varcasia 9 & Pietro Gigliotti 10 & Roberta Pellegrini 11 & Domenico Olivo 12 & Michele Colaci 13 & Giuseppe Murdaca 14 & Raffaele Brittelli 2 & Giuseppa Pagano Mariano 8 & Amelia Spinella 1 & Silvia Bellando-Randone 6 & Vincenzo Aiello 2 & Silvia Bilia 4 & Daiana Giannini 4 & Tommaso Ferrari 9 & Rodolfo Caminiti 2 & Veronica Brusi 7 & Riccardo Meliconi 7 & Poupak Fallahi 15 & Alessandro Antonelli 16 & for the COVID-19 & ASD Italian Study Group Received: 26 May 2020 / Revised: 13 July 2020 / Accepted: 17 July 2020 / Published online: 27 August 2020 # The Author(s) 2020 Abstract Introduction Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19 pandemic. Method This observational multicenter study included 1641 unselected patients with autoimmune systemic diseases from three Italian geographical areas with different prevalence of Covid-19 [high in north (Emilia Romagna), medium in central (Tuscany), and low in south (Calabria)] by means of telephone 6-week survey. Covid-19 was classified as (1) definite diagnosis of Covid-19 disease: presence of symptomatic Covid-19 infection, confirmed by positive oral/nasopharyngeal swabs; (2) highly suspected Covid-19 disease: presence of highly suggestive symptoms, in absence of a swab test. Results A significantly higher prevalence of patients with definite diagnosis of Covid-19 disease, or with highly suspected Covid19 disease, or both the conditions together, was observed in the whole autoimmune systemic disease series, compared to “Italian general population” (p = .030, p = .001, p = .000, respectively); and for definite + highly suspected diagnosis of Covid-19 disease, in patients with autoimmune systemic diseases of the three regions (p = .000, for all comparisons with the respective regional general population). Moreover, significantly higher prevalence of definite + highly suspected diagnosis of Covid-19 disease was found either in patients with various “connective tissue diseases” compared to “inflammatory arthritis group” (p < .000), or in * Alessandro Antonelli 8 UOD Reumatologia, Grande Ospedale Metropolitano, Reggio Calabria, Italy 9 U.O.S. Reumatologia, Ospedale Castrovillari, Cosenza, Italy 10 U.O.T. Specialistica Ambulatoriale ASP 201, Cosenza, Italy 11 Rheumatology Unit, School of Medicine, University of Modena & RE, Modena, Italy U.O.C. Medicina Interna “M.Valentini” P.O. Annunziata, Cosenza, Italy 12 Rheumatology Clinic ‘Madonna dello Scoglio’ Cotronei, Crotone, Italy Rheumatology Outpatient Clinic, San Giovanni di Dio Hospital, Crotone, Italy 13 Rheumatology Unit, University of Catania, Catania, Italy 14 Department of Internal Medicine, San Martino Policlinic Hospital, University of Genoa, Genoa, Italy 15 Department of Translational Research and New Technologies in Medicine and Surgery, School of Medicine, University of Pisa, Pisa,..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop